

IN THE CLAIMS:

Please cancel claims 76-90, 136-139, and 144 without prejudice, amend claims 64, 65, 68, 72, 74, 75, 91-103, and 132-135 as well as claims 71 and 73, and add new claims 145-165 as follows.

This listing of claims will replace all prior versions, and listings of the claims in the application.

Listing of the claims

1-63. (Canceled)

64. (Currently Amended) A method of inducing a cytostatic effect in a primary or metastasized colorectal, gastric or esophageal cancer cell in an individual who has primary or metastasized colorectal, gastric or esophageal cancer, said method comprising the step of: administering to said individual by ~~substantially continuous~~ infusion, a cytostatically effective amount of ~~an ST-receptor~~ a guanylyl cyclase C ligand ~~per hour for a period of time sufficient to~~ have a therapeutic effect by the cytotoxic effect of the ~~ST-receptor~~ guanylyl cyclase C, wherein ~~an ST-receptor~~ a guanylyl cyclase C ligand molecules bind to ~~ST-receptor~~ guanylyl cyclase C on the surface of a primary or metastasized colorectal, gastric or esophageal cancer cell in said individual and ~~induces~~ induce a cytostatic effect in said cells.

65. (Currently Amended) A method of inhibiting the proliferation of a primary or metastasized colorectal, gastric or esophageal cancer cell in an individual who primary or metastasized colorectal, gastric or esophageal cancer, said method comprising the step of: administering to said individual by ~~substantially continuous~~ infusion, a cytostatically effective

amount of an ~~ST-receptor~~ a guanylyl cyclase C ligand ~~per hour for a period of time~~ sufficient to have a therapeutic effect by the cytostatic effect of the ~~ST-receptor~~ guanylyl cyclase C ligand, wherein ~~ST-receptor~~ guanylyl cyclase C ligand molecules bind to ~~ST-receptors~~ guanylyl cyclase C on the surface of a primary or metastasized colorectal, gastric or esophageal cancer cell in said individual and ~~induces~~ induce proliferation of said cells.

66-67 (Canceled)

68. (Currently Amended) The method of claim 64 or 65 further comprising the step of administering a different therapeutic agent.

69. (Previously presented) The method of claim 68 wherein the therapeutic agent is 5-fluorouracil.

70. (Previously presented) The method of claim 68 wherein the therapeutic agent is bleomycin.

71. (Withdrawn - Amended) The method of claim 64 or 65 wherein said ~~ST-receptor~~ guanylyl cyclase C ligand is administered into the circulatory system of said individual.

72. (Currently Amended) The method of claim 64 or 65 wherein said ~~ST-receptor~~ guanylyl cyclase C ligand is administered intravenously.

73. (Withdrawn - Amended) The method of claim 64 or 65 wherein said ~~ST-receptor~~ guanylyl cyclase C ligand is administered intratumorally.

74. (Currently Amended) The method of claim 64 or 65 wherein said ~~ST-receptor~~ guanylyl cyclase C ligand is an ~~anti-ST-receptor~~ anti-guanylyl cyclase C antibody or a ~~an anti-guanylyl cyclase C binding~~ fragment thereof.

75. (Currently Amended) The method of claim 74 wherein said ~~ST-receptor~~ guanylyl cyclase C ligand is an ~~anti-ST-receptor~~ anti-guanylyl cyclase C monoclonal antibody.

76-90. (Canceled)

91. (Currently Amended) The method of claim 64 or 65 wherein said ~~ST-receptor~~ guanylyl cyclase C ligand is initially administered to said individual in a loading dose of at least 0.1nM per 10 kg. bodyweight of said individual.

92. (Currently Amended) The method of claim 64 or 65 wherein said loading dose is 0.1-10nM of ~~ST-receptor~~ guanylyl cyclase C ligand per 10 kg. bodyweight of said individual.

93. (Currently Amended) The method of claim 64 or 65 wherein said loading dose is 0.5-8nM of ~~ST-receptor~~ guanylyl cyclase C ligand per 10 kg. bodyweight of said individual.

94. (Currently Amended) The method of claim 64 or 65 wherein said loading dose is 1-5nM of ~~ST-receptor~~ guanylyl cyclase C ligand per 10 kg. bodyweight of said individual.

95. (Currently Amended) The method of claim 64 or 65 wherein said ~~ST-receptor~~ guanylyl cyclase C ligand is infused into said individual in a dose of .1-10nM of ST receptor ligand per 10 kg. bodyweight of said individual.

96. (Currently Amended) The method of claim 64 or 65 wherein said ~~ST-receptor~~ guanylyl cyclase C ligand is infused into said individual in a dose of .5-8nM of ~~ST-receptor~~ guanylyl cyclase C ligand per 10 kg. bodyweight of said individual.

97. (Currently Amended) The method of claim 64 or 65 wherein said ~~ST-receptor~~ guanylyl cyclase C ligand is infused into 30 said individual in a dose of 1.5nM of ~~ST-receptor~~ guanylyl cyclase C ligand per 10 kg. bodyweight of said individual.

98. (Currently Amended) The method of claim 64 or 65 wherein said ~~ST-receptor~~ guanylyl cyclase C ligand is infused into said individual for at least 8 hours.

99. (Currently Amended) The method of claim 64 or 65 wherein said ~~ST-receptor~~ guanylyl cyclase C ligand is infused into said individual for at least 12 hours.

100. (Currently Amended) The method of claim 64 or 65 wherein said ~~ST-receptor~~ guanylyl cyclase C ligand is infused into said individual for at least 16 hours.

101. (Currently Amended) The method of claim 64 or 65 wherein said ~~ST-receptor~~ guanylyl cyclase C ligand is infused into said individual for at least 20 hours.

102. (Currently Amended) The method of claim 64 or 65 wherein said ~~ST-receptor~~ guanylyl cyclase C ligand is infused into said individual for at least 24 hours.

103. (Currently Amended) The method of claim 64 or 65 further comprising administering calcium to said individual.

104-131 (Canceled)

132. (Currently Amended) The method of claim 64 wherein at least 0.1-10nM of an ~~ST-receptor~~ guanylyl cyclase C ligand per 10 kg. bodyweight of said individual are administered per hour for at least 6 hours, and a therapeutic pharmaceutical composition that comprises components which target ~~ST-receptor~~ guanylyl cyclase C for delivery of a therapeutic agent is further administered to said individual.

133. (Currently Amended) The method of claim 132 wherein said therapeutic pharmaceutical composition comprises a conjugated composition that comprises an ~~ST-receptor~~ guanylyl cyclase C binding moiety ~~and conjugated to~~ an active moiety, wherein said active moiety is a therapeutic agent.

134. (Currently Amended) The method of claim 133 wherein said ~~ST-receptor~~ guanylyl cyclase C ligand is an ~~anti-ST-receptor~~ anti-guanylyl cyclase C antibody or a an anti-guanylyl cyclase C binding fragment thereof.

135. (Currently Amended) The method of claim 134 wherein said ~~ST-receptor~~ guanylyl cyclase C ligand is an ~~anti-ST-receptor~~ anti-guanylyl cyclase C monoclonal antibody.

136-139. (Canceled)

140 (Previously presented) The method of claim 133 wherein said therapeutic agent is radiostable.

141 (Previously presented) The method of claim 133 wherein said therapeutic agent is selected from the group consisting of: compounds that cause cell death, compounds that inhibit cell division, and compounds that induce cell differentiation.

142 (Previously presented) The method of claim 133 wherein said therapeutic agent is selected from the group consisting of: chemotherapeutics, toxins and radiosensitizing agents.

143 (Previously presented) The method of claim 133 wherein said therapeutic agent is selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabioside, etoposide, 5- fluorouracil, melphalan, chlorambucil, cis-platin, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4-benzoquinone derivatives, trenimon, ricin, ricin A chain, *Pseudomonas* exotoxin, diphtheria toxin, *Clostridium perfringens* phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, nitroimidazole, metronidazole and misonidazole.

144. (Canceled)

145. (New) The method of claim 75 wherein said guanylyl cyclase C ligand is a humanized anti-guanylyl cyclase C monoclonal antibody.

146. (New) The method of claim 135 wherein said guanylyl cyclase C ligand is a humanized anti-guanylyl cyclase C monoclonal antibody.

147. (New) The method of claim 103 further comprising the step of administering a different therapeutic agent.

148. (New) The method of claim 103 wherein the therapeutic agent is 5-fluorouracil.
149. (New) The method of claim wherein said guanylyl cyclase C ligand is administered into the circulatory system of said individual.
150. (New) The method of claim 103 wherein said guanylyl cyclase C ligand is administered intravenously.
151. (New) The method of claim 103 wherein said guanylyl cyclase C ligand is an anti-guanylyl cyclase C antibody or a anti-guanylyl cyclase C binding fragment thereof.
152. (New) The method of claim 103 wherein said guanylyl cyclase C ligand is an anti-guanylyl cyclase C monoclonal antibody.
153. (New) The method of claim 103 wherein said guanylyl cyclase C ligand is initially administered to said individual in a loading dose of at least 0.1nM per 10 kg. bodyweight of said individual.
154. (New) The method of claim 103 wherein said loading dose is 0.1-10nM of guanylyl cyclase C ligand per 10 kg. bodyweight of said individual.
155. (New) The method of claim 103 wherein said loading dose is 0.5-8nM of guanylyl cyclase C ligand per 10 kg. bodyweight of said individual.

156. (New) The method of claim 103 wherein said loading dose is 1-5nM of guanylyl cyclase C ligand per 10 kg. bodyweight of said individual.

157. (New) The method of claim 103 wherein said guanylyl cyclase C ligand is infused into said individual in a dose of .1-10nM of ST receptor ligand per 10 kg. bodyweight of said individual.

158. (New) The method of claim 103 wherein said guanylyl cyclase C ligand is infused into said individual in a dose of .5-8nM of guanylyl cyclase C ligand per 10 kg. bodyweight of said individual.

159. (New) The method of claim 103 wherein said guanylyl cyclase C ligand is infused into 30 said individual in a dose of 1.5nM of guanylyl cyclase C ligand per 10 kg. bodyweight of said individual.

160. (New) The method of claim 103 wherein said ~~ST-receptor~~ guanylyl cyclase C ligand is infused into said individual for at least 8 hours.

161. (New) The method of claim 103 wherein said guanylyl cyclase C ligand is infused into said individual for at least 12 hours.

162. (New) The method of claim 103 wherein said guanylyl cyclase C ligand is infused into said individual for at least 16 hours.

163. (New) The method of claim 103 wherein said guanylyl cyclase C ligand is infused into said individual for at least 20 hours.

164. (New) The method of claim 103 wherein said guanylyl cyclase C ligand is infused into said individual for at least 24 hours.

165. (New) The method of claim 152 wherein said guanylyl cyclase C ligand is a humanized anti-guanylyl cyclase C monoclonal antibody.